Glaxo, Genmab jointly seek leukemia drug license

GlaxoSmithKline PLC and Genmab A/S said today that they had submitted a biologic license application to the U.S. Food and Drug Administration for Arzerra to treat patients whose chronic lymphocytic leukemia resists other therapies.